Categories
Markets

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is giving an update on the use of its “at-the market” equity offering plan.

As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering program under which Acasti may issue and promote from time to time its common shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been marketed at prevailing market rates averaging US$1.0747 a share. No securities were marketed in the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March five, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and will deliver the Company with supplemental freedom in its continuous review process to explore and evaluate strategic options.

About Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription drugs using OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for clients with serious HTG.

Forward Looking Statements – ACST Stock

Statements in that press release that aren’t statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking claims involve known and unknown risks, uncertainties, and other unknown factors that could cause the particular outcomes of Acasti to be materially different from historical success and as a result of any future outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this particular press release. Forward-looking statements in this press release include, but aren’t restricted to, information or statements concerning Acasti’s strategy, succeeding operations as well as its review of strategic options.

The forward-looking statements found in this press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward Looking Statements” area in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor section of Acasti’s website at www.acastipharma.com. Many forward-looking claims in that press release are made as of the particular date of this particular press release.

ACST Stock – Acasti doesn’t undertake to upgrade some such forward looking statements whether as a consequence of info which is brand new, future events or perhaps otherwise, except as required by law. The forward-looking claims contained herein are also subject generally to assumptions and risks and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

Leave a Reply

Your email address will not be published. Required fields are marked *